---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-014776"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-10-07T23:59:59+00:00"
generated_at: "2026-05-17T04:25:13.443698+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Tonix Pharmaceuticals plans Phase 2 trial of TNX-102 SL for MDD in 2026, Phase 2/3 of TNX-4800 for Lyme in 2027

## Summary
- Phase 2 trial of TNX-102 SL for major depressive disorder expected to start in 2026.
- Phase 2/3 study of TNX-4800 for seasonal Lyme disease prevention expected to start in 2027.
- TNX-102 SL is currently FDA-approved for fibromyalgia; this expands its potential indication.

## SEC filing metadata
- accession: 0001999371-25-014776
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125014776/0001999371-25-014776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125014776/tnxp-8k_100725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-014776
- JSON: https://secwatch.observer/filing/0001999371-25-014776.json
- Plain text: https://secwatch.observer/filing/0001999371-25-014776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.